Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04937127
Other study ID # DR200087 (I-LEARN)
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 8, 2021
Est. completion date January 9, 2023

Study information

Verified date January 2023
Source University Hospital, Tours
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will investigate the effects of "I-Learn cognition and behaviour" training in the care in agitation in patients with neurodegenerative diseases. This training for caregivers, aims to reduce agitation and psycho-behavioral disorders of patients living in nursing home. In addition, amount of psychotropic drugs prescribed, as well as the number of hospitalizations during the study will be assessed.


Recruitment information / eligibility

Status Completed
Enrollment 170
Est. completion date January 9, 2023
Est. primary completion date January 9, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Diagnosis of Major Neurocognitive Disorder according to DSM 5 - With agitation and NPI agitation item score of 4 or more (frequency X severity) - Information and verification of the non-opposition of the patient and his guardian / curator if he is under legal protection. Exclusion Criteria: - Patient under court protection - Inability to understand the French language - Patient whose state of health is not stabilised at the time of inclusion and/or in palliative care

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
I-LEARN training
Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part
Other:
usual care
usual care

Locations

Country Name City State
France EHPAD Résidence du Prévot Châteaugiron
France Maison Saint Michel Liffré
France EHPAD La Bourdaisière Montlouis-sur-Loire
France Résidence Père Brottier Pléchâtel
France EHPAD Le Clos Saint-Vincent Rochecorbon
France EHPAD La Source Tours
France EHPAD Montconseil Tours

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Tours

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of agitation of patients in the nursing home Assessment of agitation using the Cohen-Mansfield Agitation Inventory (CMAI, 1989) by asking caregivers about the patients' behaviour.
The minimum value is 0 and the maximum value is 203. the higher the score, the more intense the agitation
Baseline
Primary Measurement of agitation of patients in the nursing home Assessment of agitation using the Cohen-Mansfield Agitation Inventory (CMAI, 1989) by asking caregivers about the patients' behaviour.
The minimum value is 0 and the maximum value is 203. the higher the score, the more intense the agitation
3 months
Primary Measurement of agitation of patients in the nursing home Assessment of agitation using the Cohen-Mansfield Agitation Inventory (CMAI, 1989) by asking caregivers about the patients' behaviour.
The minimum value is 0 and the maximum value is 203. the higher the score, the more intense the agitation
6 months
Primary Measurement of agitation of patients in the nursing home Assessment of agitation using the Cohen-Mansfield Agitation Inventory (CMAI, 1989) by asking caregivers about the patients' behaviour.
The minimum value is 0 and the maximum value is 203. the higher the score, the more intense the agitation
9 months
Secondary Frequency and severity of Psychobehavioural Symptoms associated with Dementia Assessment using the Neuro Psychiatric Inventory, care team version (NPI-ES, 2000). 10 behavioural domains and 2 neurovegetative variables are considered. item score = frequency x severity frequency minimum = 1 and maximum = 4 severity minimum = 1 and maximum = 3 A score above 2 is pathological Baseline, 3 months, 6 months and 9 months
Secondary Quality of life of patients Assessment using the Quality of Life-Alzheimer's Disease (QOL-AD, 2009) 13 questions focus on the patient's quality of life. the patient's current quality of life in each domain is assessed by choosing one of the following four words: poor, fair, good, excellent. Baseline, 3 months, 6 months and 9 months
Secondary Impact of I-Learn on psychotropic drug prescriptions Changes in the prescriptions given to patients in terms of psychotropic drugs (addition or withdrawal of a neuroleptic, antidepressant, anxiolytic, etc.) Baseline, 3 months, 6 months and 9 months
Secondary Impact of I-Learn on psychotropic drug prescriptions Changes in the prescriptions given to patients in terms of dosage (increase/decrease of the daily dose) Baseline, 3 months, 6 months and 9 months
Secondary Impact of I-Learn training on hospital admissions number of transfers to acute or emergency departments 3 months, 6 months and 9 months
Secondary Impact of I-Learn training on hospital admissions reasons for hospitalisation 3 months, 6 months and 9 months
Secondary Impact of Psychobehavioural Symptoms Associated with Dementia on the professional practice of health care teams Assessment using the Neuro Psychiatric Inventory, care team version (NPI-ES, 2000) 10 behavioural domains and 2 neurovegetative variables are considered. item score = frequency x severity fequency minimum = 1 and maximum = 4 severity minimum = 1 and maximum = 3 A score above 2 is pathological Baseline, 3 months, 6 months and 9 months
Secondary Caregiver burnout at work Assessment using the Maslach Burnout Inventory (MBI, 1986) 22 items For each item, the minimum value is 0 and the maximum value is 6 BURNOUT Questions 1.2.3.6.8.13.14.16.20 Degree of burn out Total below 17 = low Total between 18 and 29 = moderate Total above 30 = high
DEPERSONALISATION Questions 5.10.11.15.22 Degree of burn out Total below 5 = low Total between 6 and 11 = moderate Total above 12 = high
PERSONAL FULFILMENT Questions 4.7.9.12.17.18.19.21 Degree of burn out Total above 40 = low Total between 34 and 39 = moderate Total below 33 = high
Moderate or even high scores are a sign of latent burnout that is taking hold.
Baseline, 6 months and 9 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05586750 - Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy Phase 4
Completed NCT04050800 - Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety Early Phase 1
Recruiting NCT04863859 - Persons With Dementia and Their Extended Family Caregivers
Recruiting NCT05655650 - Identifying Biomarkers in Alzheimer's Disease
Enrolling by invitation NCT03197363 - BiaƂystok PLUS - Polish Longitudinal University Study
Enrolling by invitation NCT03322306 - Establishment of Genetic Basis for Neurological Disease by Genetic Screening
Completed NCT03439163 - Large Sample PD Patients and Healthy Controls N/A
Withdrawn NCT05921929 - First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) Phase 1
Recruiting NCT05209698 - Self-Management Behaviors of Arabs and Jews With Parkinson's Disease and Their Associations With Health Outcomes
Completed NCT04362228 - The Effects of Whole-body Exercise to Improve Swallowing Function in Older Adults With Dementia N/A
Enrolling by invitation NCT05008094 - The Epidemiology of Parkinson's Disease in Croatia and the Influence of Genetic Factors and Microbiota on the Progression and Treatment Outcomes of the Disease (GiOPARK)
Completed NCT03279991 - Neuromed- Integrated Health Life Platform and Biobank
Active, not recruiting NCT04228653 - Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions Phase 1/Phase 2
Recruiting NCT05328492 - Volume Mode Non-invasive Ventilation in Amyotrophic Lateral Sclerosis N/A
Not yet recruiting NCT06151600 - A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
Recruiting NCT04880356 - Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
Active, not recruiting NCT03609125 - Cord Blood Serum in the Treatment of Neuro-Degenerative Ophthalmic Diseases. 1-Glaucoma N/A
Recruiting NCT03153670 - 3T MRI in Patients With Deep Brain Stimulation (DBS) N/A
Completed NCT03775538 - Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study Phase 1/Phase 2
Enrolling by invitation NCT04635540 - Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease N/A